ATE423099T1 - Zur behandlung von schmerzen geeignete piperazine - Google Patents
Zur behandlung von schmerzen geeignete piperazineInfo
- Publication number
- ATE423099T1 ATE423099T1 AT04814866T AT04814866T ATE423099T1 AT E423099 T1 ATE423099 T1 AT E423099T1 AT 04814866 T AT04814866 T AT 04814866T AT 04814866 T AT04814866 T AT 04814866T AT E423099 T1 ATE423099 T1 AT E423099T1
- Authority
- AT
- Austria
- Prior art keywords
- pain
- treatment
- piperazine suitable
- piperazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53303703P | 2003-12-30 | 2003-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE423099T1 true ATE423099T1 (de) | 2009-03-15 |
Family
ID=34748845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04814866T ATE423099T1 (de) | 2003-12-30 | 2004-12-17 | Zur behandlung von schmerzen geeignete piperazine |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7754723B2 (de) |
| EP (1) | EP1727801B1 (de) |
| JP (1) | JP4705043B2 (de) |
| KR (1) | KR100867188B1 (de) |
| CN (1) | CN1902178A (de) |
| AP (1) | AP2006003678A0 (de) |
| AR (1) | AR048393A1 (de) |
| AT (1) | ATE423099T1 (de) |
| AU (1) | AU2004312398B8 (de) |
| BR (1) | BRPI0417902A (de) |
| CA (1) | CA2551862A1 (de) |
| CY (1) | CY1109037T1 (de) |
| DE (1) | DE602004019576D1 (de) |
| DK (1) | DK1727801T3 (de) |
| EA (1) | EA200601249A1 (de) |
| ES (1) | ES2322907T3 (de) |
| HK (1) | HK1102580A1 (de) |
| HR (1) | HRP20090234T1 (de) |
| IL (1) | IL176582A0 (de) |
| IS (1) | IS8511A (de) |
| NO (1) | NO20063443L (de) |
| NZ (1) | NZ548169A (de) |
| PL (1) | PL1727801T3 (de) |
| PT (1) | PT1727801E (de) |
| RS (1) | RS50958B (de) |
| SI (1) | SI1727801T1 (de) |
| TW (1) | TW200536835A (de) |
| WO (1) | WO2005066130A1 (de) |
| ZA (1) | ZA200604979B (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060446A1 (en) | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
| US7157462B2 (en) * | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| ES2326979T3 (es) * | 2003-07-24 | 2009-10-22 | Euro-Celtique S.A. | Compuestos de piperidina y composiciones farmaceuticas que contienen a los mismos. |
| KR100871128B1 (ko) * | 2007-04-17 | 2008-12-03 | 한국생명공학연구원 | 4-헥사데카노일-1,1-디메틸-피페라진-1-윰 아이오다이드를포함하는 항암제 |
| AR067631A1 (es) * | 2007-07-18 | 2009-10-21 | Novartis Ag | Combinaciones sinergicas de antagonistas de vr-1 e inhibidores de cox-2 , composicion farmaceutica y uso |
| EP2184986A4 (de) * | 2007-08-06 | 2010-12-15 | Trinity Lab Inc | Pharmazeutische zusammensetzungen für die behandlung von chronischen schmerzen und von mit neuropathie einhergehenden schmerzen |
| ES2550667T3 (es) | 2010-02-18 | 2015-11-11 | Vtv Therapeutics Llc | Derivados de fenilheteroarilo y métodos de uso de los mismos |
| WO2011162409A1 (en) | 2010-06-22 | 2011-12-29 | Shionogi & Co., Ltd. | Compounds having trpv1 antagonistic activity and uses thereof |
| EP2709609B1 (de) | 2011-05-17 | 2017-10-04 | Shionogi & Co., Ltd. | Heterozyklische verbindungen |
| UA113288C2 (xx) | 2011-06-22 | 2017-01-10 | Trpv1 антагоністи, що містять дигідроксизамісник, і їх застосування | |
| WO2013023155A1 (en) | 2011-08-11 | 2013-02-14 | Xenoport, Inc. | Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| GB201709459D0 (en) * | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| AU2022267044A1 (en) | 2021-04-26 | 2023-11-30 | Pathios Therapeutics Limited | Compounds |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
| US5198459A (en) | 1987-07-11 | 1993-03-30 | Sandoz Ltd. | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents |
| DE3822792C2 (de) | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US6204284B1 (en) | 1991-12-20 | 2001-03-20 | American Cyanamid Company | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5232934A (en) | 1992-07-17 | 1993-08-03 | Warner-Lambert Co. | Method for the treatment of psychomotor stimulant addiction |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5556837A (en) | 1994-08-01 | 1996-09-17 | Regeneron Pharmaceuticals Inc. | Methods for treating addictive disorders |
| US5762925A (en) | 1994-11-03 | 1998-06-09 | Sagen; Jacqueline | Preventing opiate tolerance by cellular implantation |
| EP0833622B8 (de) | 1995-06-12 | 2005-10-12 | G.D. Searle & Co. | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
| US5955548A (en) | 1997-05-07 | 1999-09-21 | Novo Nordisk A/S | Substituted 3, 3-diamino-2-propenenitriles, their preparation and use |
| CN1259119A (zh) * | 1997-05-07 | 2000-07-05 | 诺沃挪第克公司 | 取代的3,3－二氨基－2－丙烯腈,它们的制备及用途 |
| JP4444493B2 (ja) | 1997-08-20 | 2010-03-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | カプサイシン受容体およびカプサイシン受容体関連ポリペプチドをコードする核酸配列ならびにその使用 |
| EP0943683A1 (de) | 1998-03-10 | 1999-09-22 | Smithkline Beecham Plc | Menschliches Vanilloid Rezeptorhomolog Vanilrep1 |
| GB9907097D0 (en) | 1999-03-26 | 1999-05-19 | Novartis Ag | Organic compounds |
| JP2003192673A (ja) * | 2001-12-27 | 2003-07-09 | Bayer Ag | ピペラジンカルボキシアミド誘導体 |
| DE60332316D1 (de) * | 2002-02-01 | 2010-06-10 | Euro Celtique Sa | 2-piperazinpyridine für die schmerzbehandlung |
| US7842808B2 (en) * | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| CN100457735C (zh) | 2002-06-28 | 2009-02-04 | 欧洲凯尔特公司 | 用于治疗疼痛的治疗剂 |
-
2004
- 2004-12-17 JP JP2006547210A patent/JP4705043B2/ja not_active Expired - Fee Related
- 2004-12-17 EP EP04814866A patent/EP1727801B1/de active Active
- 2004-12-17 CN CNA2004800395246A patent/CN1902178A/zh active Pending
- 2004-12-17 PL PL04814866T patent/PL1727801T3/pl unknown
- 2004-12-17 DK DK04814866T patent/DK1727801T3/da active
- 2004-12-17 BR BRPI0417902-1A patent/BRPI0417902A/pt not_active IP Right Cessation
- 2004-12-17 PT PT04814866T patent/PT1727801E/pt unknown
- 2004-12-17 DE DE602004019576T patent/DE602004019576D1/de active Active
- 2004-12-17 NZ NZ548169A patent/NZ548169A/en not_active IP Right Cessation
- 2004-12-17 AT AT04814866T patent/ATE423099T1/de active
- 2004-12-17 AP AP2006003678A patent/AP2006003678A0/xx unknown
- 2004-12-17 EA EA200601249A patent/EA200601249A1/ru unknown
- 2004-12-17 CA CA002551862A patent/CA2551862A1/en not_active Abandoned
- 2004-12-17 SI SI200431101T patent/SI1727801T1/sl unknown
- 2004-12-17 RS RSP-2009/0224A patent/RS50958B/sr unknown
- 2004-12-17 AU AU2004312398A patent/AU2004312398B8/en not_active Ceased
- 2004-12-17 WO PCT/US2004/042732 patent/WO2005066130A1/en active Application Filing
- 2004-12-17 ES ES04814866T patent/ES2322907T3/es active Active
- 2004-12-17 KR KR1020067013552A patent/KR100867188B1/ko not_active IP Right Cessation
- 2004-12-30 TW TW093141391A patent/TW200536835A/zh unknown
-
2005
- 2005-01-03 AR ARP050100007A patent/AR048393A1/es unknown
-
2006
- 2006-06-15 ZA ZA200604979A patent/ZA200604979B/en unknown
- 2006-06-15 IS IS8511A patent/IS8511A/xx unknown
- 2006-06-27 IL IL176582A patent/IL176582A0/en unknown
- 2006-06-28 US US11/478,462 patent/US7754723B2/en active Active
- 2006-07-26 NO NO20063443A patent/NO20063443L/no not_active Application Discontinuation
-
2007
- 2007-06-06 HK HK07106031.1A patent/HK1102580A1/xx not_active IP Right Cessation
-
2009
- 2009-04-22 HR HR20090234T patent/HRP20090234T1/xx unknown
- 2009-04-29 CY CY20091100477T patent/CY1109037T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE369133T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
| DE602004022061D1 (de) | Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen | |
| DE602004030907D1 (de) | Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate | |
| ATE440866T1 (de) | Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten | |
| DE602004028763D1 (de) | Te zur behandlung von virenerkrankungen | |
| DE60322451D1 (de) | 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung | |
| DE602005007717D1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
| DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| DE502005010499D1 (de) | Implantat zur Behandlung von Fettsucht | |
| DE60325770D1 (de) | Verwendung von rimexolon zur behandlung von augentrockenheit | |
| IS8511A (is) | Píperasín gagnleg til meðferðar á verkjum | |
| DE502004010131D1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| DE602005016141D1 (de) | S-mirtazapin zur behandlung von hitzewallungen | |
| ATE504297T1 (de) | Visnadin zur behandlung von kopfhautjucken | |
| DE602004022035D1 (de) | Verwendung von pthalide derivativen zur behandlung | |
| DE60238765D1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| ATE312104T1 (de) | Verbindungen zur behandlung von beeinträchtigten fundischen entspannung | |
| DE602005015434D1 (de) | Mittel zur behandlung von psychoneurotischen krankheiten | |
| ATE482707T1 (de) | 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen | |
| DE60117122D1 (de) | Verwendung von mirtazapin zur behandlung von schlafstörungen | |
| DE602004026067D1 (de) | Gerät zur Behandlung von Füßen | |
| DE602005015442D1 (de) | Kollagen-polyvinylpyrrolidon zur behandlung von osteoarthritis | |
| DE50308460D1 (de) | Verwendung von ambroxol zur behandlung von chronischen schmerzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1727801 Country of ref document: EP |